Cell and Gene Therapies | Fortrea Scroll Back to Top

Cell and Gene Therapies 

Tailored solutions for cell and gene therapy programs.

Connect with us

Expertise and services to amplify your clinical trial approaches, streamline complex processes and minimize risk. 

Strategic support

Access multidisciplinary, multimodality experience to support your studies.

Centered on patients

Get a patient-centric approach to optimize the development of your product.

Expert problem-solving

Rely on our team to navigate complex logistics and implement practical solutions.

Reduce risk for your cell and gene studies

Fortrea delivers strategic insights to enable efficient, cost-effective development of your cell and gene therapies and reduce risk across critical milestones. Our expertise across multiple modalities, clinical conduct insights, operational solutions and customized training enable us to deliver the experience you need for your study.

 

Enable seamless delivery

Apply our know-how and infrastructure 

  • Expertise with multiple modalities

    • CAR T and AAV 
    • Other viral and nonviral delivery systems (e.g., adenovirus, LNP) 
    • Cell therapies (immune cell/stem cell, autologous/allogeneic, modified/non-modified) 
    • Gene editing (e.g., CRISPR, meganucleases)
    • Advanced and complex therapeutics such as RNA-based therapies (e.g., ASOs, siRNAs), T-cell engagers and genetically modified organisms

Cell and gene therapy experience that matters

In the last 5 years, we have supported:

150+ Studies
1.4k+ Sites
15k+ Patients

Advance your cell therapy studies

Fortrea has supported and designed dozens of cell therapy programs, including all 6 FDA-approved CAR T-cell therapies.

Cell Therapies

Global gene therapy experience

No matter where you are or where you intend to go, you can rely on our global experience and expertise in advancing gene therapy trials.

Gene Therapies

Oncology in cell and gene therapy development

From targeted therapies and immunotherapies to advanced cell and gene therapies, we have helped develop biomarker-driven strategies to bring precision medicines to market.

Oncology Cell and Gene Therapies